MUMBAI: The Mumbai Zonal Unit of the Directorate of Revenue Intelligence (DRI) conducted search operations on November 16 at the Vikhroli office of pharmaceutical company Cipla Limited in Mumbai and its depot in Bhiwandi, located in Maharashtra’s Thane district. The action was carried out as part of an ongoing investigation concerning the customs classification and tariff exemption claims related to a finished drug imported from abroad. Following the operation, the company clarified that the search action will not have any material impact on its financial position, operations, or routine business activities.
Investigation Centres on Imported Finished Drug
Teams from the DRI visited both the Vikhroli office and the Bhiwandi depot to carry out detailed inspections. The primary focus of the inquiry revolves around the customs classification of an imported finished pharmaceutical formulation and the duty exemptions claimed on the product. Investigating officials are examining the specific tariff category under which the product was classified at the time of import, along with the legal and procedural grounds cited by the company to claim exemptions from customs duty.
In international trade, applicable customs duty rates are directly determined by the assigned tariff classification of an imported item. Consequently, ensuring that the classification aligns strictly with the nature of the product, its designated category, and prevailing regulatory rules is critical in the pharmaceutical sector. The DRI’s search operation was initiated to scrutinize documentation, import filings, and exemption claims associated with this specific compliance process.
Company Denies Material Impact on Operations
Addressing the regulatory action, Cipla issued a statement clarifying that the searches are not expected to cause any significant impact on its financial health or normal business operations. The company’s communication indicates that its day-to-day manufacturing, supply chain, and regular commercial activities continue without any major disruption arising from the agency’s visit.
Despite the company’s assurance, detailed information regarding the final outcome of the probe or any potential customs duty liability on the imported product has not yet emerged. The DRI has not disclosed figures related to any alleged duty differential, nor has it announced any formal demand notice or penalty amount so far. For now, the matter remains strictly at the stage of an active inquiry into the tariff classification and duty exemption claims of the imported formulation.
Investors Watch Closely for Investigation Outcome
Following Cipla’s clarification, the key factor for market participants and investors is whether the investigation eventually leads to a formal regulatory order or a financial liability. If the authorities identify any discrepancy in the tariff classification or find that the duty exemption claims were unsubstantiated, the concerned department may initiate further proceedings in accordance with the law. However, no regulatory violation or financial loss has been confirmed at this stage.
Market observers and shareholders will continue to monitor official disclosures from the company and the eventual findings of the DRI inquiry. While the pharmaceutical major has firmly ruled out any immediate operational or financial fallout, a clearer picture regarding the validity of the customs classification and exemption claims will only emerge once the agency concludes its investigation
